for females ages 35-50 (full criteria)
at San Francisco, California
study started
estimated completion
Vanessa Jacoby



PROSper is a prospective cohort study of 100 women 35-50 years of age with BRCA 1/2 mutations who have elected to either undergo risk reducing salpingo-oophorectomy (RRSO) or nonsurgical management. The investigators will compare the change in cardiovascular health, bone health, sexual function, quality of life, and menopausal symptoms over 3 years of follow-up between women who undergo RRSO (baseline just prior to surgery) and age-matched controls that do not undergo RRSO. The investigators hypothesis is that women who undergo a premature surgical menopause induced by RRSO have worse cardiovascular health and bone health compared with women who do not undergo RRSO.


BRCA1 Gene Mutation BRCA2 Gene Mutation


You can join if…

Open to females ages 35-50

  • BRCA mutation 1/2 or "Variant suspected deleterious" mutation.
  • Female
  • Age 35-50 years
  • Able to undergo RRSO
  • Speaks English
  • Able to give informed consent

You CAN'T join if...

  • Prior history of bilateral oophorectomy
  • BRCA 1/2 deleterious mutation
  • Plans to move out of geographic region in next 3 years
  • Unable to travel to study visits


  • University of California, San Francisco
    San Francisco California 94115 United States

Lead Scientist

  • Vanessa Jacoby
    Dr. Vanessa Jacoby is an obstetrician gynecologist with a research program focused on surgical gynecology. She has studied long-term health outcomes of hysterectomy and oophorectomy. She is the principal investigator of prospective cohort study of women with BRCA1 or BRCA2 mutations who undergo risk-reducing salpingo-oophorectomy funded by the American Cancer Society.


in progress, not accepting new patients
Start Date
Completion Date
University of California, San Francisco
BRCA 1 Studies at UCSF
BRCA 2 Studies at UCSF
Study Type
Last Updated